<DOC>
	<DOCNO>NCT02045251</DOCNO>
	<brief_summary>Over year , become clear first-line triple therapy lose efficacy worldwide . A capsule contain 3 agent ( Pylera® ) contain 125mg metronidazole , 140mg bismuth subcitrate potassium , 125mg tetracycline make available . The efficacy Pylera capsule study randomize control trial , quadruple Pylera therapy ( Pylera capsule PPI ) evaluate standard triple regimen . In study , 3 three-in-one capsule take four time daily ( meal bedtime ) . Given , aim assess effectiveness few pill per day Pylera capsule ( 3 Pylera capsule supplement addition amoxicillin esomeprazole twice daily ; sum 10 pills/day 10 day ) eradication H. pylorus .</brief_summary>
	<brief_title>An Open-Label Trial Of Reduced- Dose Pylera , Amoxicillin , Esomeprazole Treatment Of Helicobacter Pylori Infection</brief_title>
	<detailed_description>ABSTRACT Infection H. pylorus link chronic active gastritis , peptic ulcer disease , adenocarcinoma Non-Hodgkin 's lymphoma stomach . Eradication organism recommend patient peptic ulcer disease , low-grade gastric mucosa-associated lymphoid tissue lymphoma , atrophic gastritis , unexplained iron deficiency anemia , chronic idiopathic thrombocytopenic purpura , well first-degree relative gastric cancer patient . Guidelines still recommend use triple therapy regimen PPI , clarithromycin amoxicillin/metronidazole twice daily 7 14 day . Over year , become clear first-line triple therapy lose efficacy worldwide per protocol ( PP ) intent-to-treat ( ITT ) eradication rate less 80 % . In light low eradication rate regimen , quadruple regimen ( bismuth non bismuth base ) alternative fluoroquinolones-based regimen evolve attempt increase eradication H. pylorus . Most new quadruple regimens clarithromycin-based . Quadruple therapy improve eradication rate 85-90 % increase resistance H. pylori clarithromycin render above-mentioned regimen suboptimal . Many attempt increase number antibiotic treatment regimen face intolerability patient large number pill increase side effect ( metallic taste , nausea , etc. ) . Considering , capsule contain 3 agent ( Pylera® ) contain 125mg metronidazole , 140mg bismuth subcitrate potassium , 125mg tetracycline make available . The importance capsule lie 3 1 packaging avoidance clarithromycin use hence low risk resistance . The efficacy Pylera capsule study randomize control trial , quadruple Pylera therapy ( Pylera capsule PPI ) evaluate standard triple regimen . In study , 3 three-in-one capsule take four time daily ( meal bedtime ) . An omeprazole capsule take three single three-in-one capsule morning evening meal . Quadruple therapy ( Pylera-based ) provide superior eradication rate compare standard triple therapy ( high 80 % eradication rate versus 55 % ITT ) similar safety tolerability [ 1 ] . In aforementioned study , patient quadruple therapy take sum 14 pill per day . This big number pill per day high may threaten compliance adherence real life situation outside controlled clinical trial . This evidence difference PP ITT eradication rate ( 93 % 80 % respectively ) attribute load pill load . The sensitivity H. pylorus tetracycline amoxicillin high resistance approximately zero [ 2 ] . Our local data Lebanon show essentially resistance tetracycline amoxicillin modest rate metronidazole resistance , similar Western country ( Fig 1 ) . The use antibiotic treat H. pylorus infection promising . In addition , recently show 2 separate randomize control trial reduce half-dose antibiotic ( include 500 mg bid amoxicillin 250 mg bid metronidazole ) achieve eradication H. pylorus reduce cost reduce side effect . Fig 1 . In vitro Susceptibility H. Pylori Lebanon . Sharara AI , et al . Int J Antimicrob Agents 2000 ; 19:155-8 . Our study show decline rate H. pylorus eradication conventional triple therapy time ( Fig2 ) . Fig 2 . 10-day Legacy Triple Therapy Lebanon . Soweid A , et al . ACG 2005 [ abstract ] ; Mansour N , et al , Sharara AI . Eur J Gastroenterol Hepatol 2011 Given , aim assess effectiveness few pill per day Pylera capsule ( 3 Pylera capsule supplement addition amoxicillin esomeprazole twice daily ; sum 10 pills/day 10 day ) eradication H. pylorus . The total dose drug show Figure 3 . One hundred patient outpatient department endoscopy unit AUBMC enrol open-label single arm trial . Patients positive CLO test urea breath test , histological documentation H. pylorus infection , enrol study . The patient follow phone call day 10 side effect pill count . Patients assess presence side effect end treatment ( Day 10 ) . A urea breath test do patient ≥ 4 week therapy completion minimum 2 week PPI therapy evaluate eradication rate Eradication rate assess periodically ( every 10 patient ) confirm efficacy stop point follow : Patients 1-10 : &lt; 60 % eradication Patients 1-20 : &lt; 65 % eradication Patients 1-30 : &lt; 70 % eradication Patients 1-40 : &lt; 75 % eradication Patients 1-50 : &lt; 80 % eradication Fig 3 . Doses drug propose Pylera regimen compare previously study full-dose half-dose quadruple ( non-bismuth base ) regimen . Study Description : A- Objective : The objective study evaluate efficacy 4 tablet ( 2 capsule contain metronidazole , bismuth , tetracycline ) plus amoxicillin esomeprazole ) give twice day 10 day eradication H. pylorus . The primary end point H. pylori eradication rate ITT PP analysis . Secondary endpoint include : ( 1 ) tolerability , ( 2 ) adverse event drug regimen , ( 3 ) cost . B- Patient population : One hundred patient outpatient department endoscopy unit AUBMC enrol open-label trial . - Inclusion criterion Patients either positive CLO test , urea breath test , histopathologic documention H. pylorus infection , agree study signing inform consent . - Exclusion criterion - Age 18 old 80 year - Allergies drug use - Recent antibiotic therapy ( within 2 week enrollement ) - Severe ulcer bleed - Gastric perforation obstruction - Previous gastrectomy - Gastric cancer - Pregnancy lactation - Prior eradication therapy H. pylori - Severe concomitant disease condition make treatment unlikely effective i.e . alcoholism , drug addiction , history poor compliance . C- Design method : After documentation H. pylorus infection , primary physician introduce patient research fellow give patient clear explanation purpose study , risk , benefit . Those agree participate sign inform consent enrol study . All patient take treatment ten day . The patient assess side effect day 5 10 treatment regimen . The eradication rate assess periodically ( every 10 patient first 50 patient ) efficacy study stop target rate meet . The Pylera tablet provide free patient . However , amoxicillin esomeprazole provide freely . Patients take : - 3 Pylera capsule b.i.d ( per capsule : 125mg metronidazole , 125mg tetracycline , 140mg bismuth ; i.e . 250mg metronidazole , 250 tetracycline , 280mg bismuth b.i.d ) - Amoxicillin ( Amoxil® ) 500 g b.i.d . - PPI ( Esomeprazole 20mg b.i.d ) Compliance potential side effect evaluate phone call ( day 10 ) shortly treatment period . After minimum 4 week therapy completion , patient ask present urea breath test free charge order evaluate eradication rate H. pylorus . All patient PPI least two week test . D- Statistical Interpretation : Efficacy eradication group evaluate directly quotient patient negative urea breath test total number patient enrol group . Success therapy evaluate accord intent-to treat per-protocol analysis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Patients either positive CLO test , urea breath test , histopathologic documention H. pylorus infection , agree study signing inform consent . Age 18 old 80 year Allergies drug use Recent antibiotic therapy ( within 2 week enrollement ) Severe ulcer bleed Gastric perforation obstruction Previous gastrectomy Gastric cancer Pregnancy lactation Prior eradication therapy H. pylorus Severe concomitant disease condition make treatment unlikely effective i.e . alcoholism , drug addiction , history poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>H. pylorus</keyword>
	<keyword>Pylera</keyword>
</DOC>